{"id":892260,"date":"2025-10-03T09:17:46","date_gmt":"2025-10-03T13:17:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\/"},"modified":"2025-10-03T09:17:46","modified_gmt":"2025-10-03T13:17:46","slug":"werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\/","title":{"rendered":"Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 40th Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WATERTOWN, Mass., Oct.  03, 2025  (GLOBE NEWSWIRE) &#8212; Werewolf Therapeutics, Inc. (the \u201cCompany\u201d or \u201cWerewolf\u201d) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer and other immune-mediated conditions, today announced that three posters will be presented at the upcoming Society for Immunotherapy of Cancer\u2019s (SITC) 40th Annual Meeting, taking place November 5-9, 2025, in National Harbor, Maryland.<\/p>\n<p>Details for the poster presentations are as follows:<\/p>\n<p align=\"left\">\n        <strong>Title<\/strong>: Sequential administration of WTX-124 and mWTX-330, IL-2 and IL-12 INDUKINE\u2122 molecules, enhanced antitumor activity in mice bearing poorly immunogenic EMT6 tumors without systemic toxicity<br \/><strong>Abstract Number<\/strong>: 861<br \/><strong>Session Date and Time<\/strong>: Nov. 7, 2025; 12:15-1:45, 5:10-6:35 p.m.<br \/><strong>Location<\/strong>: Poster Hall (Exhibit Halls A and B1) <\/p>\n<p><strong>Title<\/strong>: Development of conditional T cell engagers (INDUCER\u2122 molecules) with a highly effective masking approach to reduce dose-limiting cytokine release and off-target peripheral toxicity<br \/><strong>Abstract Number<\/strong>: 964<br \/><strong>Session Date and Time<\/strong>: Nov. 8, 2025; 12:15-1:45, 5:10-6:35 p.m.<br \/><strong>Location<\/strong>: Poster Hall (Exhibit Halls A and B1)<\/p>\n<p align=\"left\">\n        <strong>Title<\/strong>: Pharmacokinetic insight into the IL-2 INDUKINE prodrug WTX-124: real-time assessment of tumor-specific activation and immune modulation<br \/><strong>Abstract Number<\/strong>: 862<br \/><strong>Session Date and Time<\/strong>: Nov. 8, 2025; 12:15-1:45, 5:10- 6:35 p.m.<br \/><strong>Location<\/strong>: Poster Hall (Exhibit Halls A and B1)<\/p>\n<p align=\"left\">\n        <strong>About Werewolf Therapeutics<\/strong>\n      <\/p>\n<p align=\"left\">Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR<sup>\u00ae<\/sup>\u00a0platform to design conditionally activated INDUKINE\u2122 and INDUCER\u2122 molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf\u2019s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company\u2019s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple solid tumor types as a single agent. Werewolf is leveraging positive data from its INDUKINE molecules to advance the development of INDUCER molecules. Werewolf\u2019s first INDUCER development candidate, WTX-1011, targets STEAP1 for prostate cancer. To learn more visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HRIo5GAuMWXQSbfOgsgryzdwcT2Mpfdo-M6fakb25Yg473akAxMYPcV2aHhcmrLUdOA6bPit5cqxFU8H1p3jYW5eKRKl2aYmW2NqO3ADLBo=\" rel=\"nofollow\" target=\"_blank\">www.werewolftx.com<\/a>.<\/p>\n<p align=\"left\">WEREWOLF\u00ae, the WEREWOLF logo, PREDATOR\u00ae, INDUKINE\u2122, INDUCER\u2122, and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.<\/p>\n<p align=\"left\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Dan Ferry<br \/>LifeSci Advisors<br \/>617.430.7576<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rSbDQlRDf8vU6IcWJHhk7xEME3WxyOx5DYEgMq9EUw7eIFrSSnuT4_aFQkLucC2rCr0IN2-fmRfi0UdN5fTAhQ0E49BEOUY0XaT9-snv-czeCE33eOPtu289_XBRrAUV\" rel=\"nofollow\" target=\"_blank\"><u>daniel@lifesciadvisors.com<\/u><\/a><\/p>\n<p align=\"left\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Amanda Sellers<br \/>Deerfield Group<br \/>301.332.5574<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tV970TqWSj3h6Yu7L11_4RtsHP9cRZnRk6aqehvlJkyzv6fiIpIv_3a1cNGqwiChazbOXvKh_r8FLyrssfseSF9qlWYgx3pA928QmWhUEtSjNNdyTr8ESz7-tNufECVguYroh2759X47mhdnK6GSiQ==\" rel=\"nofollow\" target=\"_blank\"><u>amanda.sellers@deerfieldgroup.com<\/u><\/a><\/p>\n<p align=\"left\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>Timothy Trost<br \/>Chief Financial Officer<br \/>Werewolf Therapeutics<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=K6BnJb5-ItAyXwrXGXPaVhedD6-lbvVCXVYwnAVGGfQRqUz2v9K00jyibyuWP6qVMEs8rZZynnztX4D5oNyKmQgo-QLhcXmjSo3H_nbXjpw=\" rel=\"nofollow\" target=\"_blank\"><u>ttrost@werewolftx.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTMzNyM3MTc3MzE2IzIyMDc3NDc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ODM0NjBkYzMtM2ZiNy00ODIxLWE4NmMtM2QyMGRjMGY5YWE5LTEyMTkzMDAtMjAyNS0xMC0wMy1lbg==\/tiny\/Werewolf-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) &#8212; Werewolf Therapeutics, Inc. (the \u201cCompany\u201d or \u201cWerewolf\u201d) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer and other immune-mediated conditions, today announced that three posters will be presented at the upcoming Society for Immunotherapy of Cancer\u2019s (SITC) 40th Annual Meeting, taking place November 5-9, 2025, in National Harbor, Maryland. Details for the poster presentations are as follows: Title: Sequential administration of WTX-124 and mWTX-330, IL-2 and IL-12 INDUKINE\u2122 molecules, enhanced antitumor activity in mice bearing poorly immunogenic EMT6 tumors without systemic toxicityAbstract Number: 861Session Date and Time: Nov. 7, 2025; 12:15-1:45, 5:10-6:35 p.m.Location: Poster Hall (Exhibit &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 40th Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-892260","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 40th Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 40th Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) &#8212; Werewolf Therapeutics, Inc. (the \u201cCompany\u201d or \u201cWerewolf\u201d) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer and other immune-mediated conditions, today announced that three posters will be presented at the upcoming Society for Immunotherapy of Cancer\u2019s (SITC) 40th Annual Meeting, taking place November 5-9, 2025, in National Harbor, Maryland. Details for the poster presentations are as follows: Title: Sequential administration of WTX-124 and mWTX-330, IL-2 and IL-12 INDUKINE\u2122 molecules, enhanced antitumor activity in mice bearing poorly immunogenic EMT6 tumors without systemic toxicityAbstract Number: 861Session Date and Time: Nov. 7, 2025; 12:15-1:45, 5:10-6:35 p.m.Location: Poster Hall (Exhibit &hellip; Continue reading &quot;Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 40th Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-03T13:17:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTMzNyM3MTc3MzE2IzIyMDc3NDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 40th Annual Meeting\",\"datePublished\":\"2025-10-03T13:17:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\\\/\"},\"wordCount\":468,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzOTMzNyM3MTc3MzE2IzIyMDc3NDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\\\/\",\"name\":\"Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 40th Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzOTMzNyM3MTc3MzE2IzIyMDc3NDc=\",\"datePublished\":\"2025-10-03T13:17:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzOTMzNyM3MTc3MzE2IzIyMDc3NDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzOTMzNyM3MTc3MzE2IzIyMDc3NDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 40th Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 40th Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 40th Annual Meeting - Market Newsdesk","og_description":"WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) &#8212; Werewolf Therapeutics, Inc. (the \u201cCompany\u201d or \u201cWerewolf\u201d) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer and other immune-mediated conditions, today announced that three posters will be presented at the upcoming Society for Immunotherapy of Cancer\u2019s (SITC) 40th Annual Meeting, taking place November 5-9, 2025, in National Harbor, Maryland. Details for the poster presentations are as follows: Title: Sequential administration of WTX-124 and mWTX-330, IL-2 and IL-12 INDUKINE\u2122 molecules, enhanced antitumor activity in mice bearing poorly immunogenic EMT6 tumors without systemic toxicityAbstract Number: 861Session Date and Time: Nov. 7, 2025; 12:15-1:45, 5:10-6:35 p.m.Location: Poster Hall (Exhibit &hellip; Continue reading \"Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 40th Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-03T13:17:46+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTMzNyM3MTc3MzE2IzIyMDc3NDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 40th Annual Meeting","datePublished":"2025-10-03T13:17:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\/"},"wordCount":468,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTMzNyM3MTc3MzE2IzIyMDc3NDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\/","name":"Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 40th Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTMzNyM3MTc3MzE2IzIyMDc3NDc=","datePublished":"2025-10-03T13:17:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTMzNyM3MTc3MzE2IzIyMDc3NDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTMzNyM3MTc3MzE2IzIyMDc3NDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-posters-at-the-society-for-immunotherapy-of-cancers-sitc-40th-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer\u2019s (SITC) 40th Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/892260","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=892260"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/892260\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=892260"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=892260"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=892260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}